Literature DB >> 9671043

Use of stress testing to evaluate patients with recurrent chest pain after percutaneous coronary revascularization.

S Rosanio1, M Tocchi, G A Stouffer.   

Abstract

Controversy exists regarding the diagnostic accuracy, optimal technique, and timing of noninvasive stress testing after percutaneous transluminal coronary angioplasty (PTCA). Many patients return with chest pain after PTCA, and because the incidence of restenosis has been reported to be as high as 50%, a noninvasive test with a high predictive value is needed to reduce the need for unnecessary coronary angiography. Studies have shown that the sensitivity and specificity of stress testing varies depending on the amount of time elapsed since the procedure. Soon after a successful PTCA, perfusion defects on nuclear imaging following exercise or pharmacologic stress may be detected in asymptomatic patients without angiographic restenosis. In many patients, abnormal stress myocardial perfusion scans will normalize spontaneously, and thus stress testing with nuclear imaging within 4 to 6 weeks of PTCA lacks specificity for detecting restenosis. In contrast, stress echocardiography which detects wall motion abnormalities rather than perfusion mismatch has been reported to offer more specific information on myocardial ischemia and restenosis early after PTCA. In patients who develop chest pain more than 6 weeks after PTCA, the ability to accurately identify restenosis is shared by both echocardiographic and nuclear imaging methods. The purpose of this review is to clarify the strengths, pitfalls, and prognostic value of different stress modalities and cardiac imaging techniques in patients who develop chest pain within 6 months of undergoing PTCA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671043     DOI: 10.1097/00000441-199807000-00007

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  1 in total

1.  The predictive value of exercise QRS duration changes for post-PTCA coronary events.

Authors:  Shai Efrati; Angel Cantor; Benjamin Goldfarb; Reuben Ilia
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.